An antagonist of LPA1, BMS-986020, was found to lessen the extent of the decline in the forced vital capacity of lungs in IPF patients [306] while another LPA1 antagonist AM966 attenuated bleomycin-induced vascular leakage, lung injury, inflammation and fibrosis [307]. The gene discussed is LPAR1; the disease is idiopathic pulmonary fibrosis.